Skip to main content

Advertisement

SpringerLink
Log in

Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Pancreatic acinar cell carcinoma (PACC) is a rare cancer with no specific treatment. The treatment and chemotherapy for PACC are selected according to pancreatic ductal adenocarcinoma (PDAC). Herein, we describe a recurrent PACC case of an older adult patient. The patient was treated with systemic chemotherapy, chemoradiotherapy, and maintenance therapy based on the pathologic germline BRCA2 variant, resulting in long-term survival. The pathogenic BRCA variant is detected more frequently in patients with PACC than in those with PDAC. The BRCA variant significantly impacts treatment selection and prognosis; therefore, early genomic analysis is recommended when treating PACC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Satake T, Morizane C, Rikitake R, et al. The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry. J Gastroenterol. 2022;57:890–901.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ikezawa K, Urabe M, Kai Y, et al. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment. Jpn J Clin Oncol. 2024;54:271–81.

    Article  PubMed  Google Scholar 

  3. Wisnoski NC, Townsend CM Jr, Nealon WH, et al. 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma. Surgery. 2008;144:141–8.

    Article  PubMed  Google Scholar 

  4. Huang X, Li M, Zhang L, et al. Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: a single institutional comparison to pancreatic ductal adenocarcinoma. Surg Oncol. 2021;37: 101528.

    Article  PubMed  Google Scholar 

  5. Petrova E, Wellner J, Nording AK, et al. Survival outcome and prognostic factors for pancreatic acinar cell carcinoma: retrospective analysis from the German Cancer registry group. Cancers (Basel). 2021;13:6121.

    Article  PubMed  Google Scholar 

  6. Bellotti R, Paiella S, Primavesi F, et al. Treatment characteristics and outcomes of pure Acinar cell carcinoma of the pancreas—a multicentric European study on radically resected patients. HPB (Oxford). 2023;25:1411–9.

    Article  PubMed  Google Scholar 

  7. Shin SH, Hwang HK, Jang JY, et al. Clinical characteristics of resected acinar cell carcinoma of the pancreas: a Korean multi-institutional study. Cancers (Basel). 2021;13:5095.

    Article  CAS  PubMed  Google Scholar 

  8. Takahashi H, Ikeda M, Shiba S, et al. Multicenter retrospective analysis of chemotherapy for advanced pancreatic acinar cell carcinoma: potential efficacy of platinum- and irinotecan-containing regimens. Pancreas. 2021;50:77–82.

    Article  PubMed  Google Scholar 

  9. Xu JY, Guan WL, Lu SX, et al. Optimizing chemotherapy of pancreatic acinar cell carcinoma: our experiences and pooled analysis of literature. Clin Med Insights Oncol. 2022;16:11795549221090186.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Stossel C, Raitses-Gurevich M, Atias D, et al. Spectrum of response to platinum and PARP inhibitors in germline BRCA-associated pancreatic cancer in the clinical and preclinical setting. Cancer Discov. 2023;13:1826–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Florou V, Elliott A, Bailey MH, et al. Comparative genomic analysis of pancreatic acinar cell carcinoma (PACC) and pancreatic ductal adenocarcinoma (PDAC) unveils new actionable genomic aberrations in PACC. Clin Cancer Res. 2023;29:3408–17.

    Article  CAS  PubMed  Google Scholar 

  12. Sakakida T, Ishikawa T, Doi T, et al. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan. J Gastroenterol. 2023;58:575–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kindler HL, Hammel P, Reni M, et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2022;40:3929–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sakakida T, Ishikawa T, Doi T, et al. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database. J Gastroenterol. 2023;59:145–56.

    Article  PubMed  Google Scholar 

  16. Umemoto K, Yamamoto H, Oikawa R, et al. The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling. J Natl Cancer Inst. 2022;114:1279–86.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Yamai T, Ikezawa K, Sugimoto N, et al. Utility of comprehensive genomic profiling tests for patients with incurable pancreatic cancer in clinical practice. Cancers (Basel). 2023;15:970.

    Article  CAS  PubMed  Google Scholar 

  18. Takahashi K, Takeda Y, Ono Y, et al. Current status of molecular diagnostic approaches using liquid biopsy. J Gastroenterol. 2023;58:834–47.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Skorupan N, Ghabra S, Maldonado JA, et al. Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma? J Cancer Metastasis Treat. 2023;9:5.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Mandelker D, Marra A, Zheng-Lin B, et al. Genomic profiling reveals germline predisposition and homologous recombination deficiency in pancreatic acinar cell carcinoma. J Clin Oncol. 2023;41:5151–62.

    Article  CAS  PubMed  Google Scholar 

  21. Nakayama S, Fukuda A, Kou T, et al. A case of unresectable ectopic acinar cell carcinoma developed in the portal vein in complete response to FOLFIRINOX therapy. Clin J Gastroenterol. 2023;16:610–4.

    Article  PubMed  Google Scholar 

  22. Izumo W, Higuchi R, Furukawa T, et al. A case of pathologically complete response after preoperative chemotherapy in a pancreatic acinar cell carcinoma patient with portal vein tumor thrombosis. Clin J Gastroenterol. 2022;15:642–8.

    Article  PubMed  Google Scholar 

  23. Okusaka T, Nakamura M, Yoshida M, et al. Clinical practice guidelines for pancreatic cancer 2022 from the Japan Pancreas Society: a synopsis. Int J Clin Oncol. 2023;28:493–511.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma. version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:439–57.

    Article  CAS  PubMed  Google Scholar 

  25. Pilié PG, Tang C, Mills GB, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16:81–104.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Kim KH, Kim HS, Kim SS, et al. Increased radiosensitivity of solid tumors harboring ATM and BRCA1/2 mutations. Cancer Res Treat. 2022;54:54–64.

    Article  PubMed  Google Scholar 

  27. Price JM, Prabhakaran A, West CML. Predicting tumor radiosensitivity to deliver precision radiotherapy. Nat Rev Clin Oncol. 2023;20:83–98.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Editage (www.editage.jp) for English language editing.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-Ku, Osaka, 541-8567, Japan

    Makiko Urabe, Kenji Ikezawa, Kazuhiro Kozumi, Yugo Kai, Ryoji Takada, Kaori Mukai, Tasuku Nakabori, Hiroyuki Uehara & Kazuyoshi Ohkawa

  2. Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan

    Hirofumi Akita

Authors
  1. Makiko Urabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenji Ikezawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuhiro Kozumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yugo Kai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryoji Takada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kaori Mukai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tasuku Nakabori
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroyuki Uehara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hirofumi Akita
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kazuyoshi Ohkawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception, data analysis and interpretation. MU wrote the first draft of the manuscript. KI revised the manuscript. All authors reviewed the manuscript and approved the final version.

Corresponding author

Correspondence to Kenji Ikezawa.

Ethics declarations

Conflict of interests

The authors have no conflicts of interest to disclose.

Human and animal rights

All procedures followed were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Written informed consent was obtained from the patient for the publication of this case report and accompanying images.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Urabe, M., Ikezawa, K., Kozumi, K. et al. Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma. Clin J Gastroenterol (2024). https://doi.org/10.1007/s12328-024-01981-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12328-024-01981-4

Keywords

Search

Navigation